DNLI Quote, Financials, Valuation and Earnings

Masimo Corp. has a net margin of -- compared to Denali Therapeutics, Inc.'s net margin of 14.46%. Denali Therapeutics, Inc.'s return on equity of -44.34% beat Masimo Corp.'s return on equity of -19.18%.

Denali Therapeutics, Inc. has a consensus price target of $32.21, signalling upside risk potential of 90.96%. On the other hand Masimo Corp. has an analysts' consensus of $183.75 which suggests that it could grow by 38.41%. Given that Denali Therapeutics, Inc. has higher upside potential than Masimo Corp., analysts believe Denali Therapeutics, Inc. is more attractive than Masimo Corp..

Denali Therapeutics, Inc. has a beta of 1.115, which suggesting that the stock is 11.475% more volatile than S&P 500. In comparison Masimo Corp. has a beta of 1.262, suggesting its more volatile than the S&P 500 by 26.208%.

Denali Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Masimo Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Denali Therapeutics, Inc. pays -- of its earnings as a dividend. Masimo Corp. pays out -- of its earnings as a dividend.

Denali Therapeutics, Inc. quarterly revenues are --, which are smaller than Masimo Corp. quarterly revenues of $371.5M. Denali Therapeutics, Inc.'s net income of -$126.9M is lower than Masimo Corp.'s net income of $53.7M. Notably, Denali Therapeutics, Inc.'s price-to-earnings ratio is -- while Masimo Corp.'s PE ratio is 116.80x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Denali Therapeutics, Inc. is 6.62x versus 4.20x for Masimo Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Novavax, Inc. has a net margin of -- compared to Denali Therapeutics, Inc.'s net margin of -287.29%. Denali Therapeutics, Inc.'s return on equity of -44.34% beat Novavax, Inc.'s return on equity of --.

Denali Therapeutics, Inc. has a consensus price target of $32.21, signalling upside risk potential of 90.96%. On the other hand Novavax, Inc. has an analysts' consensus of $12.78 which suggests that it could grow by 87.08%. Given that Denali Therapeutics, Inc. has higher upside potential than Novavax, Inc., analysts believe Denali Therapeutics, Inc. is more attractive than Novavax, Inc..

Denali Therapeutics, Inc. has a beta of 1.115, which suggesting that the stock is 11.475% more volatile than S&P 500. In comparison Novavax, Inc. has a beta of 2.305, suggesting its more volatile than the S&P 500 by 130.478%.

Denali Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Novavax, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Denali Therapeutics, Inc. pays -- of its earnings as a dividend. Novavax, Inc. pays out -- of its earnings as a dividend.

Denali Therapeutics, Inc. quarterly revenues are --, which are smaller than Novavax, Inc. quarterly revenues of $70.4M. Denali Therapeutics, Inc.'s net income of -$126.9M is higher than Novavax, Inc.'s net income of -$202.4M. Notably, Denali Therapeutics, Inc.'s price-to-earnings ratio is -- while Novavax, Inc.'s PE ratio is 3.86x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Denali Therapeutics, Inc. is 6.62x versus 1.09x for Novavax, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Protalix Biotherapeutics, Inc. has a net margin of -- compared to Denali Therapeutics, Inc.'s net margin of 13.19%. Denali Therapeutics, Inc.'s return on equity of -44.34% beat Protalix Biotherapeutics, Inc.'s return on equity of 12.06%.

Denali Therapeutics, Inc. has a consensus price target of $32.21, signalling upside risk potential of 90.96%. On the other hand Protalix Biotherapeutics, Inc. has an analysts' consensus of $11.00 which suggests that it could grow by 507.74%. Given that Protalix Biotherapeutics, Inc. has higher upside potential than Denali Therapeutics, Inc., analysts believe Protalix Biotherapeutics, Inc. is more attractive than Denali Therapeutics, Inc..

Denali Therapeutics, Inc. has a beta of 1.115, which suggesting that the stock is 11.475% more volatile than S&P 500. In comparison Protalix Biotherapeutics, Inc. has a beta of -0.248, suggesting its less volatile than the S&P 500 by 124.798%.

Denali Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Protalix Biotherapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Denali Therapeutics, Inc. pays -- of its earnings as a dividend. Protalix Biotherapeutics, Inc. pays out -- of its earnings as a dividend.

Denali Therapeutics, Inc. quarterly revenues are --, which are smaller than Protalix Biotherapeutics, Inc. quarterly revenues of $17.9M. Denali Therapeutics, Inc.'s net income of -$126.9M is lower than Protalix Biotherapeutics, Inc.'s net income of $2.4M. Notably, Denali Therapeutics, Inc.'s price-to-earnings ratio is -- while Protalix Biotherapeutics, Inc.'s PE ratio is 26.04x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Denali Therapeutics, Inc. is 6.62x versus 2.30x for Protalix Biotherapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Twist Bioscience Corp. has a net margin of -- compared to Denali Therapeutics, Inc.'s net margin of -27.41%. Denali Therapeutics, Inc.'s return on equity of -44.34% beat Twist Bioscience Corp.'s return on equity of -16.74%.

Denali Therapeutics, Inc. has a consensus price target of $32.21, signalling upside risk potential of 90.96%. On the other hand Twist Bioscience Corp. has an analysts' consensus of $35.88 which suggests that it could grow by 8.55%. Given that Denali Therapeutics, Inc. has higher upside potential than Twist Bioscience Corp., analysts believe Denali Therapeutics, Inc. is more attractive than Twist Bioscience Corp..

Denali Therapeutics, Inc. has a beta of 1.115, which suggesting that the stock is 11.475% more volatile than S&P 500. In comparison Twist Bioscience Corp. has a beta of 2.242, suggesting its more volatile than the S&P 500 by 124.157%.

Denali Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Twist Bioscience Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Denali Therapeutics, Inc. pays -- of its earnings as a dividend. Twist Bioscience Corp. pays out -- of its earnings as a dividend.

Denali Therapeutics, Inc. quarterly revenues are --, which are smaller than Twist Bioscience Corp. quarterly revenues of $99M. Denali Therapeutics, Inc.'s net income of -$126.9M is lower than Twist Bioscience Corp.'s net income of -$27.1M. Notably, Denali Therapeutics, Inc.'s price-to-earnings ratio is -- while Twist Bioscience Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Denali Therapeutics, Inc. is 6.62x versus 5.27x for Twist Bioscience Corp.. Usually stocks with elevated PS ratios are considered overvalued.